Results 281 to 290 of about 927,420 (325)

From HDL-cholesterol to HDL-function: cholesterol efflux capacity determinants

Current Opinion in Lipidology, 2019
Purpose of review The validity of HDL-cholesterol (HDL-C) elevation as a therapeutic target has been questioned, in comparison to enhancing HDL functionality.
D. Rhainds, J. Tardif
semanticscholar   +3 more sources

Cholesterol, high density lipoprotein-cholesterol (HDL) and cholesterol/HDL-ratio versus arterial blood pressure.

Acta Medica Scandinavica, 2009
Abstract: In a cardiovascular survey of 928 men and women aged exactly 30, 40, 50 & 60 years, a correlation between serum cholesterol, cholesterol/HDL‐ratio and arterial blood pressure was found. This correlation was indirectly caused by mutual correlations to relative weight and age as a final result found after multiple rank correlation analysis
E. Agner, H. Mørck, T. Brendstrup, H. Hollnagel, M. Schroll, F. Gyntelberg   +5 more
semanticscholar   +3 more sources

Serum cholesterol and HDL cholesterol in childhood

Irish Journal of Medical Science, 1981
Serum concentrations of total cholesterol and of HDL cholesterol have been measured in 170 Irish children, aged 1–12 years, attending hospital for conditions other than hyperlipidaemia. There were no significant differences between the sexes, or between fasting and non-fasting samples for either estimation.
D A, Kelly, H, Hooey, G, Neale, A R, McGill, M, Stuart   +4 more
openaire   +2 more sources

Increasing HDL Cholesterol Levels

New England Journal of Medicine, 2004
In the past decade, high-density lipoproteins (HDL) have emerged as a new potential therapeutic target for the treatment of cardiovascular disease. The key role of HDL as a carrier of excess cellular cholesterol in the reverse cholesterol transport pathway is believed to provide protection against atherosclerosis.
openaire   +2 more sources

Thiazolidinediones and Lowered HDL Cholesterol

Diabetes Care, 2005
Three publications, including two recently in Diabetes Care, have indicated that a combination of rosiglitazone and fibrates may lower serum HDL cholesterol in some patients (1–3). It is known that a paradoxical fall in HDL cholesterol may occur with fibrates.
Ruth L, Savage, Anne, Kiuru
openaire   +2 more sources

HDL cholesterol transport during inflammation

Current Opinion in Lipidology, 2007
The aim of this article is to review recent advances made towards understanding how inflammation and acute phase proteins, particularly serum amyloid A and group IIa secretory phospholipase A2, may alter reverse cholesterol transport by HDL during inflammation and the acute phase response.Findings suggest that the decreased apoA-I content and markedly ...
Deneys R, van der Westhuyzen, Frederick C, de Beer, Nancy R, Webb   +2 more
openaire   +2 more sources

Monocyte‐to‐HDL‐cholesterol ratio as a prognostic marker in cardiovascular diseases

Journal of Cellular Physiology, 2018
Inflammation and lipid accumulation are two basic hallmarks of atherosclerosis as a chronic disease. Inflammation not only is a local response but can also be considered as a systemic process followed by an elevation of inflammatory mediators.
S. Ganjali, A. Gotto, M. Ruscica, S. Atkin, A. Butler, M. Banach, A. Sahebkar   +6 more
semanticscholar   +1 more source

HDL-Cholesterol Levels in Gouty Patients

1984
Lipoprotein abnormalities are common in gout. The most frequent is hypertriglyceridemia, which has been reported in three-quarters of patients with primary gout (1, 2). This alteration may or may not be related to obesity, alcohol consumption, and glucose intolerance (3). Patients with gout secondary to lead nephropathy do not have hypertriglyceridemia
Carcassi, A., Boschi, S., Macri, P., Mondillo, S.   +3 more
openaire   +4 more sources

[HDL cholesterol].

Nihon rinsho. Japanese journal of clinical medicine, 2005
Hideo, Kanehara, Koji, Oida
openaire   +3 more sources